Zhitong Finance App News, Shisi Pharmaceutical Group (02005.HK) issued an announcement that the Group has obtained the drug production registration approval for latemovir injection (12ml: 240mg) from the China National Drug Administration. It is a Class 4 chemical drug, which is considered to have passed the consistency evaluation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.